The largest database of trusted experimental protocols

5 protocols using anti cd21 pe

1

Isolation and Identification of B Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mononuclear cells from bone marrow and spleen were prepared as previously reported (4 (link), 18 ). B cell sub populations were separated based on expression of specific surface proteins. Early B cell subsets in the bone marrow were identified using the scheme of Melchers (19 (link)). Transitional B cell subsets were identified using the scheme of Allman (20 (link)). Marginal zone and follicular B cells were identified using the scheme of Loder (21 (link)). The following sets of monoclonal antibodies were used: Anti-B220 (PerCP) [BD Pharmingen, San Diego, CA], anti-BP-1 (PE) (a gift from John Kearney, UAB), and anti-IgM (Cy5) [Jackson ImmunoResearch], West Grove, PA], anti-cKit (allophycocyanin) [BD Pharmingen, San Diego, CA], CD19 (SPRD) [Southern Biotech, Birmingham, AL], anti IgD (biotin) [BD Pharmingen], anti CD21 (PE) [BD Pharmingen], anti-CD25 (FITC) [BD Pharmingen, San Diego, CA], anti CD21 (PE) [BD Pharmingen, San Diego, CA], anti AA4.1 (Pecy7) [ebioscience, San Diego, CA] and anti CD23 (FITC) [BD Pharmingen, San Diego, CA].
+ Open protocol
+ Expand
2

Multicolor Flow Cytometry of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Direct immunofluorescence with specific antibodies was performed either on peripheral blood as previously described with some modifications using the following antibodies: anti-IgG1 FITC, anti-CD34-FITC, anti-IgG1-PE, anti-CD3-FITC/CD16+CD56-PE, anti-CD11C-PE, anti-CD21-PE, anti-CD20-PerCP and anti-HLA-DR-PerCP (BD Bioscience, San Jose, CA), anti-CD19-FITC, anti-CD3-APC (Invitrogen, Carlsbad, CA, anti-Lineage-FITC (anti CD3/CD14/CD16/CD19/CD20/CD56), anti-CD45-APC (Biolegend, San Diego, CA, USA) and anti-BDCA2-APC (Miltenyi Biotech, San Diego, CA, USA) [13 (link),21 (link)]. Briefly, after washing the whole blood with PBS, 100ul of blood was stained with the relevant cocktail of antibodies at 4 °C for 30 min followed by red blood cell lysis using BD FACS lysis solution (BD Bioscience, San Jose, CA, USA). Samples were acquired on Accuri C6 flow cytometer (BD Bioscience, San Jose, CA, USA) and analyzed using FCS express software (De Novo software, Glendale, CA, USA). During acquisition, a lymphocyte gate was assigned, and 10,000 events were collected for the T cells and NK cells. For DCs, a million ungated events were acquired.
+ Open protocol
+ Expand
3

Phenotypic Characterization of B-Cell Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
A total of 0.5 x 106 PBMCs were stained with the following combination of antibodies: Anti-CD19-BV421 (clone HIB19), anti-CD20-PerCPCy™5.5 (clone L27), anti-CD21-PE (clone B-ly4), anti-CD27-APC (clone M-T271) and anti-CD45-V500 (clone HI30). Anti-CD19-BV421, anti-CD20-PerCPCy™5.5, anti-CD21-PE, anti-CD27-APC, anti-CD45-V500, PerCP-Cy5.5 mouse IgG1 k isotype control, BV421 mouse IgG1 k isotype control, V500 mouse IgG1 k isotype control, PE mouse IgG1 k isotype control, and APC mouse IgG1 k isotype control were purchased from BD Biosciences (Becton Dickinson, Franklin Lakes, NJ, USA). B-cell populations were identified based on the expression of the following markers: activated memory B-cells (CD19+ CD20+ CD21- CD27+ CD45+), resting memory B-cells (CD19+ CD20+ CD21+ CD27+ CD45+), tissue-like memory cells (CD19+, CD20+ CD21- CD27- CD45+), and resting naïve B-cells (CD19+ CD20+ CD21+ CD27- CD45+).
CD34+ hematopoietic progenitors in peripheral blood were enumerated using the Stem Cell Enumeration Kit (Becton Dickinson).
All flow cytometry analyses were performed using a BD LSRFortessa™ Flow Cytometer (Becton Dickinson) from the I2MC cytometry platform (CHU Rangueil, Toulouse, France) and BD FACSDiva™ Software (Becton Dickinson).
+ Open protocol
+ Expand
4

Phenotyping of B-cell Subsets in PBMC

Check if the same lab product or an alternative is used in the 5 most similar protocols
B-cell subsets were measured in freshly thawed cryopreserved PBMCs. After washing and counting viable cells, PBMCs were surface-stained with the following conjugated mAbs: anti-CD19-PE-Cy5, anti-CD21-PE, anti-CD20-PE-Cy7, anti-CD27-APC, anti-IgM-FITC, anti-CD38-FITC, anti-HLA-DR-PE-Cy7 (BD Bioscience); anti-CD10-APC-Cy7, anti-BAFFr-APC-Cy7 (Biolegend); anti-TACI-PE, anti-CxCr5-APC (R & D Systems) and analyzed with Guava easyCyte 8HT (Millipore) and FlowJo (Treestar). Subsets were expressed as percentages of the parent CD19+ B-cell population.
+ Open protocol
+ Expand
5

Comprehensive Immunological Profiling Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum immunoglobulins (Ig) levels (IgG, IgA and IgM) were measured by immunoturbidimetry using the automatic analyzer Alinity c system (Abbott Laboratories, Chicago, IL, USA). For cellular evaluation, EDTA whole blood samples were collected. Lymphocyte subpopulations (CD4+ T, CD8+ T, B and NK cells) were performed using BD Trucount tubes and the BD Multitest 6 Color BTNK kit (BD Biosciences, San Diego, CA, USA), which included the following mixtures of fluorophore-conjugated monoclonal antibodies (mAb): anti-CD45-PerCP-Cy5.5, anti-CD3-FITC, anti-CD8-APC-Cy7, anti-CD4-PE-Cy7, anti-CD19-APC, and anti-CD16+CD56-PE. B cell phenotype was performed with an eight-color panel of the following mAb: anti-CD45-APC-H7, anti-CD19-V500, anti-CD10-V450, anti-CD38-PE-Cy7, anti-CD21-PE, anti-CD27-PerCP-Cy5, anti-IgD-FITC, and anti-IgM-APC (BD Biosciences, San Diego, CA, USA), following EURO-Class classification. Cells were acquired on a BD FACSCanto II Flow Cytometer (BD Biosciences, San Diego, CA, USA), and the InfinicytTM22.0 software was employed for multiparametric analysis (Cytognos SL, Salamanca, Spain).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!